Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

Background: Approximately 50% of ovarian cancer patients harbour homologous recombination repair deficiencies. These deficiencies have been successfully targeted using poly (ADP-ribose) polymerase inhibitors (PARPi) particularly for patients harbouring BRCA1/2 mutations. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Saravi, Sayeh, Alizzi, Zena, Tosi, Sabrina, Hall, Marcia, Karteris, Emmanouil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472031/
https://www.ncbi.nlm.nih.gov/pubmed/34572083
http://dx.doi.org/10.3390/cells10092434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472031/
https://www.ncbi.nlm.nih.gov/pubmed/34572083
http://dx.doi.org/10.3390/cells10092434

Ejemplares similares